Pemirolast

• Description:

  Pemirolast is an orally active antiallergic agent. Pemirolast attenuates Paclitaxel (HY-B0015) hypersensitivity reactions. Pemirolast can be used for bronchial asthma and conjunctivitis research[1]-[5].

• UNSPSC:

  12352005

• Target:

  Histamine Receptor

• Type:

  Reference compound

• Related Pathways:

  GPCR/G Protein; Immunology/Inflammation; Neuronal Signaling

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology; Cardiovascular Disease

• Assay Protocol:

  https://www.medchemexpress.com/pemirolast.html

• Solubility:

  DMF : < 1 mg/mL (ultrasonic)|DMSO : 100 mg/mL (ultrasonic)

• Smiles:

  O=C1C(C2=NNN=N2)=CN=C3N1C=CC=C3C

• Molecular Formula:

  C10H8N6O

• Molecular Weight:

  228.21

• References & Citations:

  [1]Kawashima T, et al. Inhibitory effect of pemirolast, a novel antiallergic drug, on leukotriene C4 and granule protein release from human eosinophils. Int Arch Allergy Immunol. 1994;103 (4) :405-9. |[2]Yanni JM, et al. Comparative effects of topical ocular anti-allergy drugs on human conjunctival mast cells. Ann Allergy Asthma Immunol. 1997 Dec;79 (6) :541-5. |[3]Fujimiya H, et al. Effect of a novel antiallergic drug, pemirolast, on activation of rat peritoneal mast cells: inhibition of exocytotic response and membrane phospholipid turnover. Int Arch Allergy Appl Immunol. 1991;96 (1) :62-7.|[4]Itoh Y, et al. Pemirolast potently attenuates paclitaxel hypersensitivity reactions through inhibition of the release of sensory neuropeptides in rats. Neuropharmacology. 2004 May;46 (6) :888-94.|[5]Tatsushima Y, et al. Pemirolast reduces cisplatin-induced kaolin intake in rats. Eur J Pharmacol. 2011 Jul 1;661 (1-3) :57-62.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  Launched

• CAS Number:

  [69372-19-6]